JP2015503507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503507A5 JP2015503507A5 JP2014548963A JP2014548963A JP2015503507A5 JP 2015503507 A5 JP2015503507 A5 JP 2015503507A5 JP 2014548963 A JP2014548963 A JP 2014548963A JP 2014548963 A JP2014548963 A JP 2014548963A JP 2015503507 A5 JP2015503507 A5 JP 2015503507A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- dihydropyrano
- carbonitrile
- pyrazole
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GMDKZHJZAGRRGP-UHFFFAOYSA-N 6-amino-3-(3,4-dimethoxyphenyl)-4-(4-fluorophenyl)-1-methyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C)C2=C1C(C=1C=CC(F)=CC=1)C(C#N)=C(N)O2 GMDKZHJZAGRRGP-UHFFFAOYSA-N 0.000 claims description 4
- OOCJZFSWSZJDAT-UHFFFAOYSA-N 6-amino-4-(4-methoxyphenyl)-1,3-diphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C=1C=CC=CC=1)=NN2C1=CC=CC=C1 OOCJZFSWSZJDAT-UHFFFAOYSA-N 0.000 claims description 4
- NZVWFTPWXPMPBG-UHFFFAOYSA-N 6-amino-4-(4-methoxyphenyl)-1-methyl-3-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C=1C=CC=CC=1)=NN2C NZVWFTPWXPMPBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- MZKALFCNIJHTJG-UHFFFAOYSA-N 2,5-diphenyl-4h-pyrazol-3-one Chemical compound O=C1CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MZKALFCNIJHTJG-UHFFFAOYSA-N 0.000 claims description 3
- SYIHKMOPWDYBOS-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-2-methyl-4h-pyrazol-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C)C(=O)C1 SYIHKMOPWDYBOS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000006688 ral GTP-Binding Proteins Human genes 0.000 claims 7
- 108010087304 ral GTP-Binding Proteins Proteins 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- GDXRSVQMDSLVIB-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-2-phenyl-4h-pyrazol-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C(=O)C1 GDXRSVQMDSLVIB-UHFFFAOYSA-N 0.000 claims 2
- NXBVNTCZEKBZTM-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-methyl-4h-pyrazol-3-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C)C(=O)C1 NXBVNTCZEKBZTM-UHFFFAOYSA-N 0.000 claims 2
- JSJKAIQJGDEDOI-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-phenyl-4h-pyrazol-3-one Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C(=O)C1 JSJKAIQJGDEDOI-UHFFFAOYSA-N 0.000 claims 2
- SYCVVGUTFUBQMP-UHFFFAOYSA-N 6-amino-1,3,4-triphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound O1C(N)=C(C#N)C(C=2C=CC=CC=2)C2=C1N(C=1C=CC=CC=1)N=C2C1=CC=CC=C1 SYCVVGUTFUBQMP-UHFFFAOYSA-N 0.000 claims 2
- XKIUDYBVYGLWGY-UHFFFAOYSA-N 6-amino-1,3-dimethyl-4-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=2C(C)=NN(C)C=2OC(N)=C(C#N)C1C1=CC=CC=C1 XKIUDYBVYGLWGY-UHFFFAOYSA-N 0.000 claims 2
- ODYQQEGFOATJHL-UHFFFAOYSA-N 6-amino-1-methyl-3,4-diphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound N#CC1=C(N)OC=2N(C)N=C(C=3C=CC=CC=3)C=2C1C1=CC=CC=C1 ODYQQEGFOATJHL-UHFFFAOYSA-N 0.000 claims 2
- ZTPKVVZQRNAVOM-UHFFFAOYSA-N 6-amino-3,4-bis(4-methoxyphenyl)-1-methyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C=1C=CC(OC)=CC=1)=NN2C ZTPKVVZQRNAVOM-UHFFFAOYSA-N 0.000 claims 2
- AZBZPRFEFCPULP-UHFFFAOYSA-N 6-amino-3,4-bis(4-methoxyphenyl)-1-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C=1C=CC(OC)=CC=1)=NN2C1=CC=CC=C1 AZBZPRFEFCPULP-UHFFFAOYSA-N 0.000 claims 2
- JRPYVPUCLKTUEM-UHFFFAOYSA-N 6-amino-3-(3,4-dimethoxyphenyl)-1-methyl-4-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C)C2=C1C(C=1C=CC=CC=1)C(C#N)=C(N)O2 JRPYVPUCLKTUEM-UHFFFAOYSA-N 0.000 claims 2
- UONYAMWNGJIPBM-UHFFFAOYSA-N 6-amino-3-(3,4-dimethoxyphenyl)-4-(4-fluorophenyl)-1-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C2=C1C(C=1C=CC(F)=CC=1)C(C#N)=C(N)O2 UONYAMWNGJIPBM-UHFFFAOYSA-N 0.000 claims 2
- APGMIYQSKPWOIM-UHFFFAOYSA-N 6-amino-3-(4-methoxyphenyl)-1,4-diphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C2=C1C(C=1C=CC=CC=1)C(C#N)=C(N)O2 APGMIYQSKPWOIM-UHFFFAOYSA-N 0.000 claims 2
- AFZCVZDIMNSNTG-UHFFFAOYSA-N 6-amino-3-(4-methoxyphenyl)-1-methyl-4-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=NN(C)C2=C1C(C=1C=CC=CC=1)C(C#N)=C(N)O2 AFZCVZDIMNSNTG-UHFFFAOYSA-N 0.000 claims 2
- PRYBIJAJECYWEP-UHFFFAOYSA-N 6-amino-3-methyl-1,4-diphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=2C(C)=NN(C=3C=CC=CC=3)C=2OC(N)=C(C#N)C1C1=CC=CC=C1 PRYBIJAJECYWEP-UHFFFAOYSA-N 0.000 claims 2
- GHGGSZZQRQFCAA-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-1,3-dimethyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=2C(C)=NN(C)C=2OC(N)=C(C#N)C1C1=CC=C(F)C=C1 GHGGSZZQRQFCAA-UHFFFAOYSA-N 0.000 claims 2
- PWCFOCGCELAIIU-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-1,3-diphenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound O1C(N)=C(C#N)C(C=2C=CC(F)=CC=2)C2=C1N(C=1C=CC=CC=1)N=C2C1=CC=CC=C1 PWCFOCGCELAIIU-UHFFFAOYSA-N 0.000 claims 2
- LGDUEGBBOZVQQA-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-1-methyl-3-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound N#CC1=C(N)OC=2N(C)N=C(C=3C=CC=CC=3)C=2C1C1=CC=C(F)C=C1 LGDUEGBBOZVQQA-UHFFFAOYSA-N 0.000 claims 2
- NEYQQEJZTHZMMT-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-3-(4-methoxyphenyl)-1-methyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=NN(C)C2=C1C(C=1C=CC(F)=CC=1)C(C#N)=C(N)O2 NEYQQEJZTHZMMT-UHFFFAOYSA-N 0.000 claims 2
- RCVFMHJNRULPOD-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-3-(4-methoxyphenyl)-1-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC=CC=2)C2=C1C(C=1C=CC(F)=CC=1)C(C#N)=C(N)O2 RCVFMHJNRULPOD-UHFFFAOYSA-N 0.000 claims 2
- SDHROKOVSZAYNC-UHFFFAOYSA-N 6-amino-4-(4-fluorophenyl)-3-methyl-1-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=2C(C)=NN(C=3C=CC=CC=3)C=2OC(N)=C(C#N)C1C1=CC=C(F)C=C1 SDHROKOVSZAYNC-UHFFFAOYSA-N 0.000 claims 2
- PKILIQNZXIGJQU-UHFFFAOYSA-N 6-amino-4-(4-methoxyphenyl)-1,3-dimethyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C)=NN2C PKILIQNZXIGJQU-UHFFFAOYSA-N 0.000 claims 2
- VDANGQOCOBTKTG-UHFFFAOYSA-N 6-amino-4-(4-methoxyphenyl)-3-methyl-1-phenyl-4h-pyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1C(C#N)=C(N)OC2=C1C(C)=NN2C1=CC=CC=C1 VDANGQOCOBTKTG-UHFFFAOYSA-N 0.000 claims 2
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 claims 2
- 101150046010 EXO84 gene Proteins 0.000 claims 2
- 102000013366 Filamin Human genes 0.000 claims 2
- 108060002900 Filamin Proteins 0.000 claims 2
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 claims 2
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 claims 2
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 claims 2
- 101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 claims 2
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 102100038914 RalA-binding protein 1 Human genes 0.000 claims 2
- 101710200757 RalA-binding protein 1 Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 102100022221 Y-box-binding protein 3 Human genes 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- NDELSWXIAJLWOU-UHFFFAOYSA-N 2,5-dimethyl-4h-pyrazol-3-one Chemical compound CN1N=C(C)CC1=O NDELSWXIAJLWOU-UHFFFAOYSA-N 0.000 claims 1
- NWXCKWDMRABXRQ-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)-4-(4-methoxyphenyl)-1,2,5,6-tetrahydropyrimidin-6-yl]phenol Chemical compound C1=CC(OC)=CC=C1C1=NC(C=2C(=CC=CC=2)OC)NC(C=2C(=CC=CC=2)O)C1 NWXCKWDMRABXRQ-UHFFFAOYSA-N 0.000 claims 1
- SGXVQHQYAMRXNE-UHFFFAOYSA-N 2-[4-(4-ethylphenyl)-2-(4-methylphenyl)-1,2,5,6-tetrahydropyrimidin-6-yl]phenol Chemical compound C1=CC(CC)=CC=C1C1=NC(C=2C=CC(C)=CC=2)NC(C=2C(=CC=CC=2)O)C1 SGXVQHQYAMRXNE-UHFFFAOYSA-N 0.000 claims 1
- PWNPNWGMUVGBAZ-UHFFFAOYSA-N 2-benzyl-5-phenyl-4h-pyrazol-3-one Chemical compound O=C1CC(C=2C=CC=CC=2)=NN1CC1=CC=CC=C1 PWNPNWGMUVGBAZ-UHFFFAOYSA-N 0.000 claims 1
- NIXIJMXBXHWPEK-UHFFFAOYSA-N 2-methyl-5-phenyl-4h-pyrazol-3-one Chemical compound C1C(=O)N(C)N=C1C1=CC=CC=C1 NIXIJMXBXHWPEK-UHFFFAOYSA-N 0.000 claims 1
- XERBEDAMDXRGFD-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-pentanoyl-8,9,10,11-tetrahydro-6h-benzo[b][1,4]benzodiazepin-7-one Chemical compound C1CCC(=O)C2=C1NC1=CC=CC=C1N(C(=O)CCCC)C2C1=CC=CC=C1Cl XERBEDAMDXRGFD-UHFFFAOYSA-N 0.000 claims 1
- CLMQBVUFKIKYLU-UHFFFAOYSA-N 6-amino-4-(2,5-dimethoxyphenyl)-3-naphthalen-2-yl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound COC1=CC=C(OC)C(C2C(=C(N)OC=3C2=C(NN=3)C=2C=C3C=CC=CC3=CC=2)C#N)=C1 CLMQBVUFKIKYLU-UHFFFAOYSA-N 0.000 claims 1
- NFPWWZIRTMIQKT-UHFFFAOYSA-N 6-amino-4-(3,5-dichloro-2-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile Chemical compound C12=C(CCC)NN=C2OC(N)=C(C#N)C1C1=CC(Cl)=CC(Cl)=C1O NFPWWZIRTMIQKT-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101150093978 RALB gene Proteins 0.000 claims 1
- 101150033538 Rala gene Proteins 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims 1
- 108010050749 geranylgeranyltransferase type-I Proteins 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578869P | 2011-12-21 | 2011-12-21 | |
| US61/578,869 | 2011-12-21 | ||
| PCT/US2012/071341 WO2013096820A1 (en) | 2011-12-21 | 2012-12-21 | Anti-cancer compounds targeting ral gtpases and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503507A JP2015503507A (ja) | 2015-02-02 |
| JP2015503507A5 true JP2015503507A5 (enExample) | 2016-02-25 |
| JP6473330B2 JP6473330B2 (ja) | 2019-02-20 |
Family
ID=48669550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548963A Expired - Fee Related JP6473330B2 (ja) | 2011-12-21 | 2012-12-21 | ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9353121B2 (enExample) |
| EP (1) | EP2793881B1 (enExample) |
| JP (1) | JP6473330B2 (enExample) |
| KR (1) | KR102097343B1 (enExample) |
| CN (1) | CN104271132B (enExample) |
| AU (1) | AU2012358317B2 (enExample) |
| CA (1) | CA2859985C (enExample) |
| WO (1) | WO2013096820A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102097343B1 (ko) | 2011-12-21 | 2020-04-07 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 |
| JP6672255B2 (ja) | 2014-07-10 | 2020-03-25 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法 |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| US10934291B2 (en) | 2014-09-25 | 2021-03-02 | Duke University | Kinase inhibitors and related methods of use |
| WO2016145252A1 (en) * | 2015-03-10 | 2016-09-15 | The Trustees Of Princeton University | Shmt inhibitors |
| WO2016205460A1 (en) * | 2015-06-16 | 2016-12-22 | Nantbioscience, Inc. | Polycyclic derivatives targeting ral gtpases and their therapeutical applications |
| KR102474326B1 (ko) | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| US10077273B2 (en) | 2016-09-14 | 2018-09-18 | The Trustees Of Princeton University | SHMT inhibitors |
| KR102507847B1 (ko) | 2016-10-28 | 2023-03-08 | 서울대학교병원 | 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| EP3558309B1 (en) | 2016-11-07 | 2023-07-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| JP7097623B2 (ja) | 2016-11-07 | 2022-07-08 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 |
| EP3534901B1 (en) | 2016-11-07 | 2022-06-22 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| EP3545693B1 (en) | 2016-11-23 | 2020-06-24 | Telefonaktiebolaget LM Ericsson (PUBL) | Method and apparatus for adaptive control of decorrelation filters |
| WO2019113174A1 (en) | 2017-12-05 | 2019-06-13 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| BR112020014561A2 (pt) * | 2018-01-17 | 2020-12-08 | Migal - Galilee Research Institute Ltd. | Nibidores inovadores da via metabólica da metionina |
| EP3740482A1 (en) | 2018-01-17 | 2020-11-25 | Migal Galilee Research Institute Ltd. | New methionine metabolic pathway inhibitors |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| SMT202300073T1 (it) | 2018-05-16 | 2023-05-12 | Forma Therapeutics Inc | Inibizione di idh-1 mutante |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| CN109305972B (zh) * | 2018-09-27 | 2021-07-09 | 广州医科大学 | 一种二氢吡喃并吡唑类化合物及其制备方法和应用 |
| CN109734676B (zh) * | 2019-01-16 | 2021-01-29 | 四川大学 | 苯并二氮杂卓类衍生物及其制备方法和应用 |
| EP4076416A4 (en) * | 2019-12-19 | 2024-04-10 | The Trustees of Indiana University | SMALL MOLECULAR COVALENT INHIBITION OF RAL GTPASEN |
| CN111406752B (zh) * | 2020-04-23 | 2021-07-23 | 中国农业科学院植物保护研究所 | 二氢吡咯并吡唑酮类衍生物作为几丁质酶抑制剂或杀线虫剂的应用 |
| US20230293490A1 (en) * | 2020-08-17 | 2023-09-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Profilin1:actin inhibitor as an anti-angiogenic compound |
| WO2022108730A1 (en) * | 2020-11-18 | 2022-05-27 | Texas Tech University System | Therapies for cancer using small molecules that bind to and inhibit ral interacting proteins |
| WO2023004188A2 (en) * | 2021-07-23 | 2023-01-26 | The Research Institute At Nationwide Children's Hospital | Inhibiting intracellular pathogens |
| EP4476223A4 (en) * | 2022-02-07 | 2026-04-08 | Univ Cornell | MALIC ENZYME INHIBITORS 1 |
| CN117919423A (zh) * | 2024-01-24 | 2024-04-26 | 上海交通大学医学院附属新华医院 | Ral抑制剂在骨丢失中的应用 |
| CN120168481B (zh) * | 2025-05-14 | 2025-08-19 | 天津医科大学 | 一种抑制REXO4消解R-loop酶活性的小分子及其在制备肿瘤药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US362503A (en) * | 1887-05-10 | Sectional boat | ||
| US361185A (en) * | 1887-04-12 | Poueths to john h | ||
| US4555396A (en) * | 1982-12-22 | 1985-11-26 | Eastman Kodak Company | Use of pyrylium and thiapyrylium compounds as biological stains |
| US5750550A (en) * | 1995-09-15 | 1998-05-12 | Sanofi | 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof |
| JPH10279480A (ja) * | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
| US6143471A (en) | 1998-03-10 | 2000-11-07 | Mitsubishi Paper Mills Limited | Positive type photosensitive composition |
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US20070105105A1 (en) | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| CA2533803A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| KR20080015123A (ko) * | 2005-05-25 | 2008-02-18 | 다나베 미츠비시 세이야꾸 가부시키가이샤 | 피라졸론 유도체를 포함하는 의약 |
| WO2007016539A2 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
| US20090221559A1 (en) | 2005-09-02 | 2009-09-03 | Jean-Francois Bonfanti | Benzodiazepines as hcv inhibitors |
| WO2007056188A1 (en) | 2005-11-04 | 2007-05-18 | President And Fellows Of Harvard College | Synthesis of inhibitors of ftsz |
| WO2007081966A2 (en) | 2006-01-09 | 2007-07-19 | University Of Southern California | Small molecules for treating cancer and abnormal cell proliferation disorders |
| WO2008143894A2 (en) | 2007-05-14 | 2008-11-27 | Dana-Farber Cancer Institute, Inc. | Phosphorylated rala |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011010715A1 (ja) | 2009-07-24 | 2011-01-27 | 国立大学法人 東京大学 | Ｐr－Ｓｅｔ７阻害剤 |
| US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| WO2012078902A2 (en) | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| US20150011411A1 (en) | 2011-12-21 | 2015-01-08 | THE REGENTS OF THE UNIVERSITY OF COLORADO a body corporation | Biomarkers of cancer |
| KR102097343B1 (ko) | 2011-12-21 | 2020-04-07 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| EP2858981A1 (en) | 2012-06-06 | 2015-04-15 | Basf Se | Pyrazolopyrans having herbicidal and pharmaceutical properties |
| CN103910737B (zh) | 2014-03-25 | 2016-08-17 | 浙江师范大学 | 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用 |
-
2012
- 2012-12-21 KR KR1020147020271A patent/KR102097343B1/ko not_active Expired - Fee Related
- 2012-12-21 JP JP2014548963A patent/JP6473330B2/ja not_active Expired - Fee Related
- 2012-12-21 EP EP12859252.4A patent/EP2793881B1/en active Active
- 2012-12-21 CN CN201280070263.9A patent/CN104271132B/zh not_active Expired - Fee Related
- 2012-12-21 AU AU2012358317A patent/AU2012358317B2/en not_active Ceased
- 2012-12-21 WO PCT/US2012/071341 patent/WO2013096820A1/en not_active Ceased
- 2012-12-21 CA CA2859985A patent/CA2859985C/en active Active
- 2012-12-21 US US14/366,035 patent/US9353121B2/en not_active Expired - Fee Related
-
2016
- 2016-04-29 US US15/142,011 patent/US10689392B2/en not_active Expired - Fee Related
-
2020
- 2020-05-12 US US15/930,188 patent/US11964985B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| JP5992054B2 (ja) | ピラゾロピロリジン化合物 | |
| JP6171003B2 (ja) | ピロロピロリジノン化合物 | |
| US8859586B2 (en) | Cyclohexyl isoquinolinone compounds | |
| US9556180B2 (en) | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | |
| US9403827B2 (en) | Substituted purinone compounds | |
| JP2014520860A (ja) | タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物 | |
| EA201290179A1 (ru) | Производные 2,3,4-бензотиадиазепин-2,2-диоксида | |
| HK1198761B (en) | Imidazopyrrolidinone compounds |